Differentiation state and invasiveness of human breast cancer cell lines - PubMed (original) (raw)

Comparative Study

doi: 10.1007/BF00666165.

Affiliations

• PMID: 7881109
• DOI: 10.1007/BF00666165

Comparative Study

Differentiation state and invasiveness of human breast cancer cell lines

C L Sommers et al. Breast Cancer Res Treat. 1994.

Abstract

Eighteen breast cancer cell lines were examined for expression of markers of epithelial and fibroblastic differentiation: E-cadherin, desmoplakins, ZO-1, vimentin, keratin and beta 1 and beta 4 integrins. The cell lines were distributed along a spectrum of differentiation from epithelial to fibroblastic phenotypes. The most well-differentiated, epithelioid cell lines contained proteins characteristic of desmosomal, adherens and tight junctions, were adherent to one another on plastic and in the basement membrane matrix Matrigel and were keratin-positive and vimentin-negative. These cell lines were all weakly invasive in an in vitro chemoinvasion assay. The most poorly-differentiated, fibroblastic cell lines were E-cadherin-, desmoplakin- and ZO-1-negative and formed branching structures in Matrigel. They were vimentin-positive, contained only low levels of keratins and were highly invasive in the in vitro chemoinvasion assay. Of all of the markers analyzed, vimentin expression correlated best with in vitro invasive ability and fibroblastic differentiation. In a cell line with unstable expression of vimentin, T47DCO, the cells that were invasive were of the fibroblastic type. The differentiation markers described here may be useful for analysis of clinical specimens and could potentially provide a more precise measure of differentiation grade yielding more power for predicting prognosis.

PubMed Disclaimer

Similar articles

• Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines.
  Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP. Sommers CL, et al. Cancer Res. 1992 Oct 1;52(19):5190-7. Cancer Res. 1992. PMID: 1382837
• Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities.
  Sommers CL, Thompson EW, Torri JA, Kemler R, Gelmann EP, Byers SW. Sommers CL, et al. Cell Growth Differ. 1991 Aug;2(8):365-72. Cell Growth Differ. 1991. PMID: 1793731
• Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.
  Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al. Thompson EW, et al. J Cell Physiol. 1992 Mar;150(3):534-44. doi: 10.1002/jcp.1041500314. J Cell Physiol. 1992. PMID: 1537883
• Collagen induced MMP-2 activation in human breast cancer.
  Thompson EW, Yu M, Bueno J, Jin L, Maiti SN, Palao-Marco FL, Pulyaeva H, Tamborlane JW, Tirgari R, Wapnir I, et al. Thompson EW, et al. Breast Cancer Res Treat. 1994;31(2-3):357-70. doi: 10.1007/BF00666168. Breast Cancer Res Treat. 1994. PMID: 7881112 Review.

Cited by

• Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer.
  Kotsifaki A, Maroulaki S, Karalexis E, Stathaki M, Armakolas A. Kotsifaki A, et al. Int J Mol Sci. 2024 Aug 27;25(17):9302. doi: 10.3390/ijms25179302. Int J Mol Sci. 2024. PMID: 39273251 Free PMC article. Review.
• Identification of lysyl oxidase as an adipocyte-secreted mediator that promotes a partial mesenchymal-to-epithelial transition in MDA-MB-231 cells.
  Van Stiphout CM, Kelly G, Pallegar NK, Elbakry E, Vilchis-Celis AV, Christian SL, Viloria-Petit AM. Van Stiphout CM, et al. Explor Target Antitumor Ther. 2024;5(1):1-19. doi: 10.37349/etat.2024.00201. Epub 2024 Jan 16. Explor Target Antitumor Ther. 2024. PMID: 38468823 Free PMC article.
• Chemical profiling of volatile compounds of the essential oil of grey-leaved rockrose (Cistus albidus L.) and its antioxidant, anti-inflammatory, antibacterial, antifungal, and anticancer activity in vitro and in silico.
  Elbouzidi A, Taibi M, Laaraj S, Loukili EH, Haddou M, El Hachlafi N, Naceiri Mrabti H, Baraich A, Bellaouchi R, Asehraou A, Bourhia M, Nafidi HA, Bin Jardan YA, Chaabane K, Addi M. Elbouzidi A, et al. Front Chem. 2024 Feb 15;12:1334028. doi: 10.3389/fchem.2024.1334028. eCollection 2024. Front Chem. 2024. PMID: 38435667 Free PMC article.
• Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade.
  Batalha S, Gomes CM, Brito C. Batalha S, et al. Front Immunol. 2023 Oct 31;14:1267621. doi: 10.3389/fimmu.2023.1267621. eCollection 2023. Front Immunol. 2023. PMID: 38022643 Free PMC article.
• Novel In Vitro Models for Cell Differentiation and Drug Transport Studies of the Human Intestine.
  Przybylla R, Krohn M, Sellin ML, Frank M, Oswald S, Linnebacher M. Przybylla R, et al. Cells. 2023 Sep 27;12(19):2371. doi: 10.3390/cells12192371. Cells. 2023. PMID: 37830585 Free PMC article.

References

1. 1. Cancer Res. 1990 Sep 15;50(18):6087-94 - PubMed
2. 1. Cancer Res. 1991 May 1;51(9):2395-402 - PubMed
3. 1. Cell. 1991 Jul 12;66(1):107-19 - PubMed
4. 1. Annu Rev Biochem. 1990;59:237-52 - PubMed
5. 1. Anticancer Res. 1992 Nov-Dec;12(6B):1973-82 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information